Eisai

Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.

Source: https://www.eisai.com/company/index.html

donepezilAricept

acetylcholinesterase inhibitor

Aricept (donepezil) is an acetylcholinesterase inhibitor originally from Eisai. Taken once daily by mouth, it raises the level of acetylcholine in the brain and is used to treat mild, moderate, and severe dementia of the Alzheimer's type.

Donepezil is a tablet that blocks an enzyme called acetylcholinesterase, which normally breaks down acetylcholine — a chemical the brain uses for memo

lenvatinibLenvima

multi-kinase inhibitor

Lenvima (lenvatinib) is an oral multi-kinase inhibitor from Eisai that blocks VEGF and FGF receptors driving tumour blood supply. It is used in radioactive iodine-refractory thyroid cancer, advanced kidney cancer and, with pembrolizumab, in endometrial cancer.

Cancers depend on new blood vessels and on growth signals received through receptor proteins. Lenvatinib blocks several of these receptors, including

2 medicines explained